


## Koios DS<sup>™</sup>Breast

**FDA-cleared.** The first and only patented, proprietary, clinical decision support (DS) software using AI and machine learning to help radiologists analyze ultrasound images. Clinically proven to improve patient outcomes and streamline workflow.

Increase diagnostic accuracy
Decrease the time to treatment

✓ Eliminate unnecessary procedures
✓ Less Clerical, More Clinical<sup>™</sup>



## **#SmartUltrasound**



## Greater accuracy and confidence

Machine learning-derived risk assessment aligned to a BI-RADS® category



## **Confidence Level Indicator**

Patented feature shows a lesion's risk on a continuum within each assessment category



## Automated reporting

System-generated size, shape, orientation and BI-RADS alignment to save, export or dismiss



## Improved patient experience

Earlier detection, faster treatment and proven to reduce benign biopsies by up to 31%



## Secure IT deployment

Premise-based web application sits behind your firewall – no PHI leaves your network



## Makes nice with your technology

Connects with all major PACS and prepopulates findings into reporting systems

# Koios Engine >450,000

images from pathology-proven cases used to train the system

>17,900

unique features analyzed per physician-selected lesion seconds to interpret and assess risk of malignancy

## Research proven: FDA landmark reader study

Clinically proven to offer statistically significant improvement in physician accuracy – as measured by AUC (area under the receiver operating characteristic curve), while also reducing both inter- and intra-operator variability.


#### Methodology

- 15 physicians
- 3 to 39 years of experience
- 900 cases, randomized and interpreted twice by each reader
- First read without, second read with Koios DS
- 4-week "washout" period between rounds
- · All cases pathology-proven or a minimum of 1-year follow-up

#### Physicians using Koios DS Breast . . .

- Significantly improved diagnostic performance
- Detected up to an additional 6 cancers per 100 presented
- Could potentially reduce benign biopsies up to 31%
- Improved consistency of interpretation

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K190442 Data on file at Koios Medical. Available upon request.



## Less Clerical, More Clinical



#### Flexible AI workflow

Deploy on PACS and/or directly on ultrasound scanner hardware

## ſh

#### Up to 40% fewer clicks/keystrokes

Our Workflow 2.0 reduces overall clicks and/or keystrokes when moving an ultrasound exam through into the final report

## Contact us for a product demo or customer testimonials.



in Koios Medical

@koiosmed